Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

CompletedOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

February 28, 2021

Study Completion Date

March 31, 2022

Conditions
HIV-1-infection
Interventions
DRUG

Dolutegravir 50mg Tab

The subjects starts their ART with this drugs, once a day

DRUG

Lamivudine 300 mg

The subjects starts their ART with this drugs, once a day

Trial Locations (24)

18008

Hospital Universitario Virgen de Las Nieves, Granada

18014

Hospital Campus de la Salud, Granada

26006

Hospital San Pedro, Logroño

29010

Hospital Universitario Virgen de la Victoria, Málaga

30003

Hospital Reina Sofía, Murcia

30120

"Hospital Clínico Universitario Virgen de la Arrixaca", El Palmar

03570

Hospital Marina Baixa, Villajoyosa

Unknown

Hospital Universitario Torrecárdenas, Almería

Hospital de Jerez, Cadiz

Hospital Universitario Puerto Real, Cadiz

Hospital Universitario Reina Sofia, Córdoba

Hospital Comarcal Santa Ana de Motril, Granada

Hospital de Jaen, Jaén

Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria

Hospital Universitario Puerta de Hierro, Madrid

Hospital Costa del Sol, Málaga

Hospital Comarcal de Melilla, Melilla

Hospital Universitario de melilla, Melilla

Hospital General Universitario Santa Lucía, Murcia

Hospital de Son Llàtzer, Palma de Mallorca

Hospital Universitario de Canarias, Santa Cruz de Tenerife

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitario y Politécnico de La Fe, Valencia

Hospital Clínico Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
lead

University Hospital Virgen de las Nieves

OTHER

NCT04002323 - Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients | Biotech Hunter | Biotech Hunter